title: Association of lipoprotein(a) with atherothrombotic events and fibrinolytic variables. A case-control study.
abstract: Elevated plasma levels of lipoprotein(a) [Lp(a)] have been associated with an increased risk of cardiovascular disease. The aim of the present study was to investigate whether Lp(a) plasma levels were associated with subsequent ischemic events and with fibrinolytic variables in patients with established atherosclerotic disease enrolled in the prospective PLAT study. Lp(a) levels and fibrinolytic variables in 37 atherosclerotic patients who subsequently developed an atherothrombotic event during the first year of follow-up (cases) were compared with those in paired controls, matched for age, sex, diagnosis at enrollment and lipid pattern, who remained free from vascular events during the same time frame. Median and mean Lp(a) levels were similar in cases (6.05 mg/dl; 13.8 +/- 19.4 mg/dl) and controls (6.05 mg/dl; 17.1 +/- 21.6 mg/dl). In the whole group plasma Lp(a) levels correlated significantly with the increase of t-PA antigen (r = 0.368; p = 0.002) and fibrinolytic activity (r = 0.410; p = 0.001) induced by venous stasis but not with baseline fibrinolytic variables. These findings indicate that in patients with established atherosclerotic disease Lp(a) may interfere in vivo with the fibrinolytic process but is not predictive of subsequent ischemic events.
authors.affiliation: E. Grossi Paoletti Center, Institute of Pharmacological Sciences, University of Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Franceschini
authors.forename: E
authors.initials: E
authors.lastname: Cofrancesco
authors.forename: O
authors.initials: O
authors.lastname: Safa
authors.forename: C
authors.initials: C
authors.lastname: Boschetti
authors.forename: E
authors.initials: E
authors.lastname: Tremoli
authors.forename: L
authors.initials: L
authors.lastname: Mussoni
authors.forename: C R
authors.initials: CR
authors.lastname: Sirtori
authors.forename: M
authors.initials: M
authors.lastname: Cortellaro
mesh_terms: D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood* / Q000150:complications; D001798:Blood Proteins / Q000032:analysis; D016022:Case-Control Studies; D002561:Cerebrovascular Disorders / Q000097:blood / Q000453:epidemiology / Q000401:mortality; D015897:Comorbidity; D016757:Death, Sudden, Cardiac / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007558:Italy / Q000453:epidemiology; D008055:Lipids / Q000097:blood; D017270:Lipoprotein(a) / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000453:epidemiology* / Q000401:mortality; D009765:Obesity / Q000453:epidemiology; D016491:Peripheral Vascular Diseases / Q000097:blood / Q000453:epidemiology / Q000601:surgery; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D011446:Prospective Studies; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D013927:Thrombosis / Q000097:blood / Q000453:epidemiology*
chemical_list: D001798:Blood Proteins; D008055:Lipids; D017270:Lipoprotein(a); D017395:Plasminogen Activator Inhibitor 1